COCP - Cocrystal NIAID ink pact to explore COVID-19 protease inhibitors in preclinical studies

Cocrystal Pharma (NASDAQ:COCP) signed an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) for preclinical studies evaluating the potential of  its 3CL protease inhibitors to treat COVID-19. The company said it applied its proprietary drug discovery platform technology to develop novel, broad-spectrum SARS-CoV-2 3CL protease inhibitors. Under the Non-Clinical Evaluation Agreement (NCEA), Cocrystal provided its 3CL protease inhibitors and the NIAID, a division of the National Institutes of Health, will be responsible for in vitro and in vivo studies evaluating the antiviral activity of the compounds. "Studies to date show that our protease inhibitors exhibit superior in vitro potency against SARS-CoV-2 and variants of concern including Omicron," said Cocrystal's President and co-interim CEO Sam Lee.

For further details see:

Cocrystal, NIAID ink pact to explore COVID-19 protease inhibitors in preclinical studies